louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06210893: Upwards Laryngeal Handshake Technique and Simple Palpation for Locating the Cricoid Cartilage
Official title: Upwards Laryngeal Handshake Technique and Simple Palpation for Locating the Cricoid Cartilage : a Randomized Comparative Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Technique for Locating the Cricoid Cartilage
Lead sponsor: SMG-SNU Boramae Medical Center
Sponsor class: OTHER
First posted: 2024-01-18
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study aims to compare upwards laryngeal handshake technique and simple palpation for locating the cricoid cartilage.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing general anesthesia

Exclusion Criteria:

* History of neck surgery
* Anatomical anomaly or skin lesion in the neck
* History of gastroesophageal reflux disease

Primary outcomes:
measure: Success rate for the correct identification of the cricoid cartilage
timeFrame: At 1 minute after induction of anesthesia
Secondary outcomes:
measure: Distance from the cricoid cartilage center
timeFrame: At 1 minute after induction of anesthesia
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01790893: Treatment for Presumed Ocular Histoplasmosis
Official title: Intravitreal Aflibercept Injection for the Treatment of cHoroidAl Neovascularization seconDary to Presumed ocuLar Histoplasmosis syndromE.(the HANDLE Study)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Ocular Histoplasmosis
Keywords: Histoplasmosis
Lead sponsor: Retina Associates of Kentucky
Sponsor class: OTHER
First posted: 2013-02-13
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.


Eligibility criteria: Inclusion Criteria:

* Active choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis demonstrated by active leakage on fluorescein angiography with spectal domain OCT evidence of subretinal or intraretinal fluid or PED.
* Active CNV may also be defined as demonstrating active subretinal hemorrhage.
* ETDRS Best corrected visual acuity 20/20-20/320.
* willing and able to comply with all study clinic visits and study related procedures.
* Willing to use and practice more than one form of contraceptives during the 13 month study for male and female.
* Provide signed informed consent
* Able to understand and complete study related questionnaires

Exclusion Criteria:

* Under 18 years of age
* CNV due to other causes than Presumed Ocular Histoplasmosis
* Previous treatment in the study eye within 6 months prior to Day 1
* More than 5 Intravitreal injections of anti-VEGF therapy within previous 12 months
* Any clinical evidence of any other ocular condition other than Ocular histoplasmosis
* History of allergy to fluorescein
* Pregnant( or planning on becoming pregnant within the next 13 months) or breast feeding women
* Sexually Active Men or Women who are NOT willing to practice more than one form of contraceptives during the next 13 months.
* Anticipated or previous (within previous 3 months) systemic anti-VEGF therapy

Primary outcomes:
measure: ocular and systemic adverse events
timeFrame: through Month 12
Secondary outcomes:
measure: Visual acuity
timeFrame: Months 3, 6, 9 and 12
Other outcomes:
measure: OCT changes
timeFrame: baseline to 12 months
Locations:
city: Augusta
country: United States
facility: Southeast Retina
state: Georgia
city: Lexington
country: United States
facility: Retina Associates of Kentucky
state: Kentucky
city: Cincinnati
country: United States
facility: Cincinnati Eye Institute
state: Ohio
Study officials:
affiliation: Retina Associates of Kentucky
name: John W Kitchens, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03003793: Insulin Sensitivity in Patients With Atopic Dermatitis
Official title: Insulin Sensitivity in Patients With Atopic Dermatitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atopic Dermatitis/Eczema
Type 2 Diabetes
Lead sponsor: University Hospital, Gentofte, Copenhagen
Sponsor class: OTHER
First posted: 2016-12-28
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with atopic dermatitis are recruited from Department of Dermatology and Allergology at Gentofte Hospital.

Control subjects are recruited from the Danish recruitment site "www.forsoegsperson.dk".

Brief summary: The incidence of atopic dermatitis and type 2 diabetes, respectively, has increased over many years. Novel research shows an association between the two conditions. While this relationship at least in theory can be explained by lifestyle factors, there is reason to believe that other pathophysiological mechanisms are involved. Hence, our hypothesis is that patients with atopic dermatitis are insulin resistant due to their chronic inflammatory state. Insulin resistance might play an unknown part in the increased frequency of type 2 diabetes among patients with atopic dermatitis. In the present project, the investigators aim to measure insulin sensitivity by means of the 'golden standard' hyperinsulinaemic euglycaemic clamp in patients suffering from atopic dermatitis compared to a healthy control group (matched case-control study). The project is a close collaboration between The Department of Dermatology and Allergy and Center for Diabetes Research at Gentofte Hospital.


Eligibility criteria: Inclusion Criteria:

* Moderate to severe atopic dermatitis for at least 5 years
* BMI \< 30 kg/m2
* HbA1c \< 42 mmol/mol

Exclusion Criteria:

* Diabetes
* Prediabetes
* First-degree relatives with diabetes
* Chronic inflammatory diseases other than atopic dermatitis and asthma
* Pregnancy
* Breast-feeding
* Daily intake of medications that are known to influence the glucose metabolism are not allowed one month before the study (e.g. asthma medicines and hormonal contraception).

Primary outcomes:
measure: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls
timeFrame: Baseline, plasma glucose every 5 minutes, insulin/C-peptide, glucagon every 10-15 minutes throughout a 3 hour hyperinsulinaemic euglycaemic clamp
Secondary outcomes:
Other outcomes:
Locations:
city: Hellerup
country: Denmark
facility: Center for Diabetes Research, Gentofte Hospital, University of Copenhagen
Study officials:
affiliation: University Hospital, Gentofte
name: Filip K Knop, MD, PhD
role: STUDY_DIRECTOR
affiliation: University Hospital, Gentofte
name: Jacob P Thyssen, MD,PhD,DMSc
role: STUDY_DIRECTOR
References:
Clinical trial NCT01807793: Targeted Management Intervention for African-American Men With TIA or Stroke
Official title: Targeted Management Intervention for African-American Men With TIA or Stroke.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Transient Ischemic Attack (TIA)
Keywords: Stroke
TIA
African American
Lead sponsor: Case Western Reserve University
Sponsor class: OTHER
Collaborators: name: National Institute of Nursing Research (NINR)
First posted: 2013-03-08
Enrollment: 43
Sex: MALE
Minimum age (years): 22
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Stroke is the leading cause of disability, third leading cause of death, and one of the most resource-intensive diseases among Americans. African-Americans (AA) have a stroke rate nearly double that of Euro-Americans (EA), and AA who experience a first-ever stroke are younger, have greater stroke disability, more post-stroke complications, and slower recovery compared to EA.


Eligibility criteria: Inclusion Criteria:

* Self-identified AA male
* Between 22 and 64 years of age (\> age 21 and \< age 65).
* Within 6 months of discharge for Stroke /TIA
* Planned or recent home discharge
* Barthel Index (BI) score of \> 60
* Available care partner willing to participate
* Be able to speak and understand English

Exclusion Criteria:

* Individuals who are unable or unwilling to provide written informed consent

Primary outcomes:
measure: Medication adherence
timeFrame: Screening/baseline, 3 months, 6 months
Secondary outcomes:
measure: Biological and health behaviors parameters
timeFrame: Baseline, 3 months, 6 months
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Case Western Reserve University
state: Ohio
Study officials:
References:
Clinical trial NCT04253093: Comparison of Rocuronium Induced Neuromuscular Blockade in Late Second Trimester Pregnant and Non-pregnant Women
Official title: Comparison of Rocuronium Induced Neuromuscular Blockade in Late Second Trimester Pregnant and Non-pregnant Women
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pregnancy Related
Lead sponsor: Hallym University Kangnam Sacred Heart Hospital
Sponsor class: OTHER
First posted: 2020-02-05
Enrollment: 50
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: case: late second trimester pregnant women undergoing general anesthesia control: non-pregnant women undergoing general anesthesia

Brief summary: The present study is to compare the onset and duration of rocuronium in late second trimester women and non-pregnant women undergoing general anesthesia.

Detailed description: Pregnancy induces physiological changes. Plasma volume, cardiac output, hepatic blood flow and protein binding are changed from the first trimester of pregnancy. These physiological changes give effect to the onset and duration of neuromuscular blocking drugs.

Rocuronium is a commonly used neuromuscular blocking drug categorized as FDA category B. Rocuronium is widely used for pregnant women. Previous studies have evaluated the onset and duration of rocuronium in postpartum women. Lately, the investigators have evaluated the onset and duration of rocuronium in early second trimester pregnant women and the duration was significantly longer in early second trimester women compared to non-pregnant women.

Since there is little research on the onset and duration of rocuronium in the late second trimester pregnant women, the investigators planned the present research.

Eligibility criteria: Inclusion Criteria:

* women undergoing general anesthesia

Exclusion Criteria:

* liver disease
* renal disease
* diabetes mellitus
* asthma
* allergic to specific drugs
* BMI\>30 or \<18

Primary outcomes:
measure: duration of rocuronium
timeFrame: time measured to 25% recovery with T1 using Train of Four watch, assessed upto 1 hour
Secondary outcomes:
measure: onset of rocuronium
timeFrame: time measured to 0% depression of T1 using Train of Four watch, assessed upto 5 minutes
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kangnam sungshim hospital
Study officials:
affiliation: professor
name: Eunmi Choi
role: STUDY_CHAIR
References:
Clinical trial NCT01326793: Internet-Based Depression Screening for College Students
Official title: Internet-Based Depression Screening for College Students
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Major Depressive Disorder
Keywords: telepsychiatry
MDD
Depression
Major Depressive Disorder
Skype
college
university
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2011-03-31
Enrollment: 1900
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: This study aims to determine whether using telecommunication tools, specifically web pages containing online screening instruments and real-time video chat, will be an efficient way to implement Major Depressive Disorder screening among college students. The study also aims to determine if proactive depression screening and free online consultation with a psychiatrist will increase the rate of help-seeking among college students with MDD.

Eligible participants will complete a demographics survey and depression screening assessment online. Those subjects who express suicidality or depressive symptoms will be offered the opportunity to complete a one-time psychiatric consultation with Skype video-conferencing.


Eligibility criteria: Inclusion criteria:

* All who consider themselves current undergraduate from Massachusetts colleges are encouraged to participate.

Primary outcomes:
measure: 9-item Patient Health Questionnaire
timeFrame: Baseline, Week 8
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Depression Clinical and Research Program at Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Albert Yeung, MD, ScD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Shyu I, Soo JY, Fava M, Kvedar J, Yeung A. Internet Based Depression Screening for College Students. Proceedings of the 163rd Annual Meeting of the American Psychiatric Association (APA). New Orleans, LA, 2010.
citation: Soo JY, Shyu, I, Kvedar J, Fava M, Yeung A. The use of Facebook to advertise depression screening among college students: A feasibility and effectiveness study. Proceedings of the 62nd Annual Meeting of the Institute of Psychiatric Services (IPS). Boston, MA, 2010.
Clinical trial NCT04006093: Apixaban in Subjects With Peritoneal Dialysis
Official title: Pharmacokinetics of Apixaban in Subjects With End-stage Renal Disease Treated With Peritoneal Dialysis: the ApiDP Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Chronic Renal Insufficiency
Peritoneal Dialysis
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
Collaborators: name: University Hospital, Rouen
First posted: 2019-07-02
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two groups of participants will receive one single-dose of 5 mg of apixaban: the first group of participants with a normal renal function, the second group contains participants with end-stage renal disease treated with peritoneal dialysis.
Primary purpose: OTHER

Brief summary: The primary objective of this study is to assess the pharmacokinetics of a single oral dose of apixaban (5mg) in participants with dialysis peritoneal versus participants with normal renal function.

Detailed description: Participants with chronic renal disease treated with peritoneal dialysis and participants with normal renal function are hospitalized for three days.

Eligibility criteria: Inclusion Criteria:

* Participant with 21\<BMI\<40
* French participant
* Participant able to consent
* Participant with social insurance
* Participant on peritoneal dialysis for at least 3 months with end-stage renal disease treated

Exclusion Criteria:

* Participant with hypersensibility reactions to apixaban
* Participant with a history of major bleeding
* Participant already on anticoagulant
* Participant on non-stearoid anti-inflammatory at anti-inflammatory dosage \> 300 mg
* Participant on potent inhibitors of CYP 3A4 and P-gp
* Participant on inducers of CYP3A4 and P-sp
* Participant with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
* Participant receiving or having received antibiotic treatment within 14 days prior to study
* Pregnant or lactating women
* Participant with known hypersensitivity reactions to icodextrin
* Participant not supporting an intraperitoneal volume of 2 liters (only participant with peritoneal dialysis)
* Participant with "Normal renal function" with glomerular filtration rate \< 90 ml/min

Primary outcomes:
measure: Apixaban area Under the curve
timeFrame: Day 3
measure: Apixaban maximum plasma concentration
timeFrame: Day 3
Secondary outcomes:
measure: anti-Xa activity
timeFrame: Hour 0, Hour 3, Hour 9 and Hour 72
measure: TP activity
timeFrame: Hour 0, Hour 3, Hour 9 and Hour 72
measure: TCA activity
timeFrame: Hour 0, Hour 3, Hour 9 and Hour 72
measure: Apixaban urinary elimination
timeFrame: Day 3
measure: Apixaban maximum peritoneal concentration
timeFrame: day 3
Other outcomes:
Locations:
city: Caen
country: France
facility: CHU Caen
Study officials:
References:
Clinical trial NCT06531993: Effect of Pectin in Chronic Kidney Disease Patients ( Stage 3 and 4 )
Official title: Effect of Pectin in Chronic Kidney Disease Patients ( Stage 3 and 4 )
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Chronic Kidney Diseases
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-08-01
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Pectin, a class of heteropolysaccharides based on polygalacturonic acid, is a safe and non-toxic natural food additive recommended by the Joint FAO/WHO Committee on Food Additives with no daily additive limit . Pectin is mainly obtained from apple pomace, citrus peels and sugar beets, ancurrently, commercial pectin contains ≥65% Gal-A (galacturonic acid)
Primary purpose: TREATMENT

Brief summary: Effect of pectin in chronic kidney disease patients

Detailed description: Chronic kidney disease (CKD) is a serious global health problem leading to serious comorbidities, end-stage renal disease (ESRD), and death

From 1990 to 2016, the prevalence of CKD increased by 90% worldwide, which is closely tied to the increase in at-risk populations with diabetes mellitus (DM), hypertension (HTN), and prediabetes . It is estimated to be around 9.1 to 13.4%. This means there are about 700 million to over 800 million cases of CKD worldwide.

In 2017, CKD resulted in 1.2 million deaths and was the 12th leading cause of death worldwide . And in the same year, the estimated prevalence of CKD in Egypt was 7.1 million individuals, which means 106 patients/1000 population .

Pectin, a class of heteropolysaccharides based on polygalacturonic acid, is a safe and non-toxic natural food additive recommended by the Joint FAO/WHO Committee on Food Additives with no daily additive limit . Pectin is mainly obtained from apple pomace, citrus peels and sugar beets, ancurrently, commercial pectin contains ≥65% Gal-A (galacturonic acid).

Among the patients who tried to take the pectin, unexpectedly was found that the pectin had a significant effect on the rapid reduction of blood creatinine concentration in patients with chronic kidney disease. So, the authors followed up the physical examination indeces of chronic kidney disease patients who took the Pectin .

Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of CKD patients (stage 3 and 4)
2. age between 18 and 60 years
3. Must be able to swallow tablets

Exclusion Criteria:

1- End stage renal disease ( stage 5 ) 2 - Patients with renal transplantation 3- pregnancy 4- Presence of malignancy

Primary outcomes:
measure: effect of pectin in GFR improvement in ckd patients
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Prof
name: Ashraf Anwer Thabet
role: STUDY_DIRECTOR
References:
Clinical trial NCT06963593: Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy
Official title: Efficacy and Safety of Nanosized Megestrol Acetate Combined With Immunochemotherapy in the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer: A Randomized, Controlled, Multicenter Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Advanced Gastroesophageal Cancer
Lead sponsor: Peking University
Sponsor class: OTHER
First posted: 2025-05-09
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a prospective, randomized, parallel-controlled, multicenter clinical study. The purpose of this study is to evaluate the efficacy and safety of nanocrystalline megestrol acetate combined with the first-line standard immunochemotherapy regimen compared with the first-line standard immunochemotherapy regimen in the treatment of anorexia and cachexia in advanced gastric and esophageal cancer. Eligible patients with gastric and esophageal cancer will be randomly assigned in a 1:1 ratio to the nanocrystalline megestrol acetate combination group (referred to as the megestrol acetate group for short) or the first-line standard immunochemotherapy group (referred to as the standard control group for short).


Eligibility criteria: 1. Aged between 18 and 75 years old, regardless of gender；
2. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0-2；
3. The expected survival time is more than 3 months；
4. Good organ function

Primary outcomes:
measure: Improvement in Quality of Life for Patients with Advanced Gastric Cancer and Esophageal Cancer
timeFrame: 1year
measure: Changes in Body Weight Relative to Baseline in Patients with Advanced Gastric and Esophageal Cancers
timeFrame: 1year
Secondary outcomes:
measure: Impact on Survival Benefits in Patients with Advanced Gastric and Esophageal Cancers
timeFrame: 1year
measure: Impact on Survival Benefits in Patients with Advanced Gastric and Esophageal Cancers
timeFrame: 1year
measure: Impact on Body Composition in Patients with Advanced Gastric and Esophageal Cancers
timeFrame: 1year
measure: Impact on Body Composition in Patients with Advanced Gastric and Esophageal Cancers
timeFrame: 1year
Other outcomes:
Locations:
Study officials:
References: